The Effect of Gliatamin (Chonline Alphoscerate) on Depressive Mood in Type 2 Diabetes Patients
Status:
Unknown status
Trial end date:
2019-06-30
Target enrollment:
Participant gender:
Summary
The aim of this study is to investigate the effect of Gliatamin (chonline alphoscerate) on
depressive mood in type 2 diabetes patients and demonstrate the impact of improved depressive
mood could be influence the patient's quality of life and glycemic control.